Phase 2 N=128 Valproic Acid for the Prevention of Post-Amputation Pain
Pain, Phantom · Pain, Neuropathic
Primary: Number of Patients With Chronic Post-amputation Pain — 37; 36 Participants — p=0.53
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=20 A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of Desipramine
Cancer
Primary: Plasma Pharmacokinetics of LY2603618: the Maximum Concentration of LY2603618 in the Plasma (Cmax) — 5950 nanograms/milliliter (ng/mL)
Phase 1 N=88 Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients
Advanced Cancer
Primary: Area Under Plasma Concentration Time Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib: Cycle 2 Day 1 — 3552; 2712; 3238; 2305 nanogram*hour per…
N/A N=1,584 Impact of an Atrial Fibrillation Decision Support Tool (AFDST) on Thromboprophylaxis for Atrial Fibrillation
Atrial Fibrillation · Atrial Flutter
Primary: Changes in Discordant Antithrombotic Therapy — 291; 335; 277; 329 participants — p=0.02
N/A N=171 Clinical Performance Evaluation of Two Silicone Hydrogel Lenses
Visual Acuity
Primary: Overall CLUE Comfort — 65.0; 60.3 Units on a Scale
Phase 2 N=24 Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder
Attention Deficit Hyperactivity Disorder (ADHD)
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) at the Specified Dose Level — 10; 11; 7; 6 Participants
Phase 2 N=36 Vidaza to Restore Hormone Thx Prostate
Prostate Cancer
Primary: Percentage of Patients With PSA Doubling Time >=3 Months. — 55.8 % of patients with PSA-DT>= 3 months
Phase 3 N=288 A Study of LY2216684 in Participants With Major Depression Disorder
Major Depressive Disorder
Primary: Number of Participants With Clinically Significant Events — 0; 1; 0; 1 Participants
Phase 2 N=22 Triferic Pediatric Pharmacokinetic Protocol
End Stage Renal Disease
Primary: Pharmacokinetics (PK) of Triferic Iron Administered IV in Pediatric CKD-5HD Patients: Cmax. — 217; 114 microgram/deciliter
N/A N=89 Pilot Study of an Intimacy Enhancement Intervention for Couples Facing Breast Cancer
Breast Cancer
Primary: Feasibility of the Treatment as Measured Through Study Accrual — 62 Participants
N/A N=64 Evaluating Plaque Photoablation Using an Excimer Laser in Patients With Lower Extremity Vascular Disease
Peripheral Arterial Disease
Primary: Crossing the Target Lesion — 60 Participants
Phase 4 N=100 Apremilast in Palmo-Plantar Psoriasis
Palmo-plantar Psoriasis
Primary: Palmoplantar Psoriasis Physician Global Assessment (PPPGA) of 0 or 1 — 7; 2 Participants
N/A N=49 Efficacy of Injected Local Anesthetic vs Topical Anesthetic in Cosmetic Injectable Fillers.
Anesthesia
Primary: Participants Anesthetic Preference — 32; 16 participant preference selection
Phase 3 N=75 Recovery of Diaphragmatic Function After Neuromuscular Blockade and Sugammadex
Diaphragmatic Dysfunction · Muscle Weakness · Muscle Fatigue
Primary: Electric Activity of the Diaphragm (Microvolts) — 3.7; 4.5; 3.2; 2.9 microvolt
N/A N=809 Is Iron Deficiency the Cause of Anemia Among Women in Cambodia?
Anemia · Iron Deficiency · Hemoglobin Disorder
Primary: Hemoglobin Levels at 12-weeks. Marginal Means (95% CI). — 123; 116; 121; 116 g/L — p=<0.05